These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 17165635)
1. Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review. Falagas ME; Siempos II; Bliziotis IA; Panos GZ Mayo Clin Proc; 2006 Dec; 81(12):1567-74. PubMed ID: 17165635 [TBL] [Abstract][Full Text] [Related]
2. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. Falagas ME; Matthaiou DK; Bliziotis IA J Antimicrob Chemother; 2006 Apr; 57(4):639-47. PubMed ID: 16501057 [TBL] [Abstract][Full Text] [Related]
3. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study. Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691 [TBL] [Abstract][Full Text] [Related]
4. Role of beta-lactam agents in the treatment of community-acquired pneumonia. Garau J Eur J Clin Microbiol Infect Dis; 2005 Feb; 24(2):83-99. PubMed ID: 15696306 [TBL] [Abstract][Full Text] [Related]
5. Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Lujan M; Gallego M; Fontanals D; Mariscal D; Rello J Crit Care Med; 2004 Mar; 32(3):625-31. PubMed ID: 15090938 [TBL] [Abstract][Full Text] [Related]
6. Severe pneumococcal pneumonia: impact of new quinolones on prognosis. Olive D; Georges H; Devos P; Boussekey N; Chiche A; Meybeck A; Alfandari S; Leroy O BMC Infect Dis; 2011 Mar; 11():66. PubMed ID: 21406091 [TBL] [Abstract][Full Text] [Related]
7. Decrease in drug resistance in pneumococcal community-acquired pneumonia. Obando I; Arroyo L; Sanchez-Tatay D Chest; 2007 Jul; 132(1):359; author reply 359-60. PubMed ID: 17625101 [No Abstract] [Full Text] [Related]
8. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae. File TM Clin Infect Dis; 2002 Mar; 34 Suppl 1():S17-26. PubMed ID: 11810607 [TBL] [Abstract][Full Text] [Related]
10. Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial. Groeneveld GH; van der Reyden TJ; Joosten SA; Bootsma HJ; Cobbaert CM; de Vries JJC; Kuijper EJ; van Dissel JT J Antimicrob Chemother; 2019 Aug; 74(8):2385-2393. PubMed ID: 31106377 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. Mills GD; Oehley MR; Arrol B BMJ; 2005 Feb; 330(7489):456. PubMed ID: 15684024 [TBL] [Abstract][Full Text] [Related]
12. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains? Falcó V; Almirante B; Jordano Q; Calonge L; del Valle O; Pigrau C; Planes AM; Gavaldà J; Pahissa A J Antimicrob Chemother; 2004 Aug; 54(2):481-8. PubMed ID: 15215226 [TBL] [Abstract][Full Text] [Related]
13. Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased? Vallès X; Marcos A; Pinart M; Piñer R; Marco F; Mensa JM; Torres A Chest; 2006 Sep; 130(3):800-6. PubMed ID: 16963678 [TBL] [Abstract][Full Text] [Related]
14. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Martínez JA; Horcajada JP; Almela M; Marco F; Soriano A; García E; Marco MA; Torres A; Mensa J Clin Infect Dis; 2003 Feb; 36(4):389-95. PubMed ID: 12567294 [TBL] [Abstract][Full Text] [Related]
15. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Waterer GW; Somes GW; Wunderink RG Arch Intern Med; 2001 Aug 13-27; 161(15):1837-42. PubMed ID: 11493124 [TBL] [Abstract][Full Text] [Related]
16. β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. Nie W; Li B; Xiu Q J Antimicrob Chemother; 2014 Jun; 69(6):1441-6. PubMed ID: 24535276 [TBL] [Abstract][Full Text] [Related]
17. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173 [TBL] [Abstract][Full Text] [Related]
18. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis. Raz-Pasteur A; Shasha D; Paul M Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096 [TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. Feldman C J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171 [TBL] [Abstract][Full Text] [Related]